TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05488834

Intervention type: OTHER
Group type: OTHER
Intervention: Critical-Care Pain Observation Tool
Description: The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness.
Study: NCT06279338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)
Study: NCT05300022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeKnO T1D: Parents
Description: app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
Study: NCT05143502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate
Description: fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
Study: NCT05662995

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed with the patient in supine position (with or without left uterine displacement, depending on clinical circumstances). A phased-array transducer will be used for lung ultrasound and will be used for the assessment of B-lines, which arise from the pleural line and extend to the bottom of the screen and move with the sliding lung
Study: NCT05533190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wysa AI chatbot mental health app
Description: Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
Study: NCT05521373

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound cervical selective nerve root block
Description: A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound and fluoroscopy-guided cervical selective nerve root block
Description: The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
Study: NCT05040191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Education(control)
Description: The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptic interactive virtual reality simulation training
Description: Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptic interactive computer-based simulation training
Description: Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill.
Study: NCT05324202

Intervention type: DEVICE
Group type: OTHER
Intervention: Cynosure Cynergy Nd:YAG Laser 1064nm
Description: The Nd:YAG Laser 1064nm is intended to be used as a treatment option in individuals suffering from low-risk basal cell carcinoma(s).
Study: NCT05359068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 4 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 1 valsartan capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127 tablet
Description: 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 1 valsartan capsule
Study: NCT05151614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
Study: NCT05759832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified HFNC oxygen therapy
Description: In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.

Intervention type: DEVICE
Group type: OTHER
Intervention: Face mask
Description: In the face mask group, oxygen was delivered via a face mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen \> 90%.
Study: NCT05193487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inferior alveolar nerve block
Description: inferior alveolar nerve block using Articaine 4% with 1/200000 Adrenaline and a traditional needle injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-osseous mandibular anaesthesia
Description: intra-osseous mandibular anaesthesia using Articaine 4% with 1/200000 Adrenaline and a special intra-osseous injection device
Study: NCT06520280

Intervention type: OTHER
Group type: OTHER
Intervention: polyamide and 3D printed complete denture
Description: pts. receive 2 sets of complete dentures made from polyamide and 3d printed to use

Intervention type: OTHER
Group type: OTHER
Intervention: polyamide and 3D printed complete denture
Description: pts. receive 2 sets of complete dentures made from polyamide and 3d printed to use
Study: NCT06364527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Digital Health respiratory disease management platform
Description: The Aptar Digital Health respiratory disease management platform is a digital health tool that combines a Healthcare Professional portal (BreatheSmart Connect) and an associated patient mobile application (BreatheSmart mobile application). The Aptar Digital Health respiratory disease management platform is intended to be used in conjunction with compatible connected sensor devices that track medication adherence and for some, technique.
Study: NCT05548894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint
Description: upper acrylic splint rest on the maxillary teeth and had flat surface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint and laser therapy
Description: the stabilization splint used in combination of treatment with laser therapy
Study: NCT02516436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine NX
Description: Buprenorphine with naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine
Study: NCT05602896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sepsis education
Description: The education program has been reviewed and approved by BJH Center for Practice Excellence
Study: NCT05874570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotics for H. pylori eradication
Study: NCT05757362

Intervention type: OTHER
Group type: OTHER
Intervention: Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)
Description: An online application of the developed questionnaire form
Study: NCT04829578

Intervention type: OTHER
Group type: OTHER
Intervention: Hypnosis
Description: Chronic idiopathic pruritus is treated by hypnosis
Study: NCT05883826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual health training
Description: The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
Study: NCT05373238

Intervention type: PROCEDURE
Intervention: Early discharge
Description: Early discharge

Intervention type: PROCEDURE
Intervention: Early discharge
Description: Early discharge
Study: NCT06196502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch (GHT)
Description: Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior. GHT Hepatitis-B vaccine will start 5 minutes before the application and continue during and after the procedure. It is planned to take 10 minutes in total. The researcher will place one hand on the baby's head and the other hand on the baby's lower abdomen, covering the waist and hips, for 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Care
Description: Kangaroo care will be provided to randomly selected volunteer moms in their own gynecological ward rooms, where they will have skin-to-skin contact with their babies while maintaining their privacy. Kangaroo care is a strategy that promotes bonding and engagement between a mother and her infant by allowing skin-to-skin contact with the newborn's face facing the mother and only the diaper remaining.~The infant is positioned such that his or her shoulders are totally on the mother's chest, ensuring the baby's airway is open. To avoid heat loss while the baby is in skin-to-skin contact with his mother, a tiny blanket will be placed on his back and a beanie will be placed on his head. Kangaroo care will begin 5 minutes before the Hepatitis-B vaccine is administered and will continue throughout the operation. It is estimated that it will take 10 minutes in total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactation
Description: Breastfeeding will become standard medical practice. Breastfeeding will start as soon as the baby is given the vaccination and continue throughout the process.
Study: NCT04430907

Intervention type: BIOLOGICAL
Intervention: HPV 9-valent Vaccine, Recombinant
Description: After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey.
Study: NCT04881838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P regimen
Description: Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course A1 + Vin
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course B1 +Vin
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course A2 + Vin
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course B2 +Vin
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
Study: NCT05699681

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic and transesophageal echocardiography
Description: After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~* Apical four chamber (A4C) view~* Apical two chamber view (A2C) view~* Right ventricle (RV) focused A4C view~* Right ventricular systolic pressure (RVSP)~* Pulmonary arterial acceleration time (PAAT),~* Tricuspid annular plane systolic excursion (TAPSE),~* Tricuspid annular plane systolic velocity (s'),~* Right ventricular fractional area change (RV FAC)~* RV free wall strain,~* RV myocardial performance index (MPI),~* RV isovolumic relaxation time (IVRT),~* RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon.
Study: NCT04881838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course A3 + Vin
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Course B3 +Vin
Description: vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Description: Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
Study: NCT05154968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate buffer
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Administered SC infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Administered SC infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Autoinjector
Description: Used to administer the drug through SC infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Autoinjector
Description: Used to administer the drug through SC infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Autoinjector
Description: Used to administer the drug through SC infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Autoinjector
Description: Used to administer the drug through SC infusion.
Study: NCT06086262

Intervention type: DEVICE
Intervention: Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)
Description: The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force.
Study: NCT04821284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT04821284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perflubutane Microbubble
Description: Oxaliplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05595759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Violence against women education supported by creative drama
Description: Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine service operation
Description: No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.